Detalles de la búsqueda
1.
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Ann Hematol
; 102(6): 1395-1408, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37119314
2.
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Br J Haematol
; 193(5): 915-921, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33782950
3.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Eur J Haematol
; 107(6): 617-623, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34418168
4.
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
Eur J Haematol
; 98(1): 57-66, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27428357
5.
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Br J Haematol
; 169(5): 683-8, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25817799
6.
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Blood
; 122(7): 1284-92, 2013 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23843494
7.
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Eur J Haematol
; 94(3): 243-50, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25082346
8.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 781-787, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38278960
9.
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Blood
; 118(12): 3228-35, 2011 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-21685374
10.
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
J Clin Invest
; 132(17)2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36047494
11.
Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Eur J Haematol
; 83(2): 99-107, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19385987
12.
Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
Bone Marrow Transplant
; 54(11): 1764-1774, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30962502
13.
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Oncoimmunology
; 8(9): e1638210, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31428530
14.
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 925, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38418611
15.
Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
Biochem Biophys Res Commun
; 366(3): 848-51, 2008 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18082628
16.
TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.
Int J Med Sci
; 5(2): 87-91, 2008 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-18414650
17.
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
J Cancer Res Clin Oncol
; 143(8): 1543-1554, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28337541
18.
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Leukemia
; 35(8): 2416-2418, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33589755
19.
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Mol Cancer Ther
; 14(5): 1181-91, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25761894
20.
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Haematologica
; 89(5): 520-7, 2004 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15136214